The opening of a new facility by Cytek Biosciences in Wuxi, China, is a significant development for the company. This expansion is likely to improve its production capabilities, enabling it to meet the growing demand for its products in the Asian market more efficiently. Additionally, the strategic location in China could provide Cytek Biosciences with better access to local markets and resources, potentially leading to increased sales and a stronger market position in the region. Given these factors, the short-term impact on CTKB's stock price is expected to be positive, reflecting investor optimism about the company's growth prospects and expanded operational capabilities.